On April 27, 2016, Biotricity Inc. appointed Dr. Norman M. Betts as director to fill one of two vacancies on the Board of Directors of the Registrant. Dr. Betts, age 62, is an associate professor, Faculty of Business Administration, University of New Brunswick and a Chartered Accountant Fellow (FCA). Dr. Betts serves as a director of Tanzanian Royalty Exploration Corporation, a mineral resource company with exploration stage properties, the common shares of which are listed on the Toronto Stock Exchange under the symbol TNX and on the NYSE MKT LLC under the symbol TRX. He is also a director and Chair of the audit committees of Tembec Inc. Dr. Betts was also appointed to the Board of Directors of the Bank of Canada and currently serves as a member of the audit and finance committee and the pension committee. Additionally, Dr. Betts was a member of the New Brunswick Legislative Assembly from 1993 to 2003 and held three different cabinet posts, including minister of finance from 1999 to 2001. He was awarded a PhD in Management from the School of Business at Queen's University in 1992. On May 3, 2016, the company appointed Mr. David A. Rosa as director to fill the remaining vacancy on the Board of Directors of the Registrant. Mr. Rosa, was the President and CEO of Sunshine Heart Inc., from October 2009 through November 2015. From 2008 to November 2009, Mr. Rosa served as chief executive officer of Milksmart Inc., a company that specializes in medical devices for animals. From 2004 to 2008, Mr. Rosa served as the vice president of global marketing for cardiac surgery and cardiology at St. Jude Medical. He is a member of the Board of Directors of QXMedical, LLC.
Biotricity Inc. is a medical technology company focused on biometric data monitoring and diagnostic solutions. The Company developed its Bioflux technology, comprised of a monitoring device and software components. The Bioflux device is comprised of a wet electrode worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patientâs electrocardiogram (ECG) data for monitoring and diagnostic purposes. Its Bioflux platform has a built-in cellular chipset and a real-time embedded operating system, which allows for its technology to be utilized as an Internet of Things (IoT) platform. It has developed several technologies, including Biotres, Bioheart, and Biocare. Biotres is an ECG Holter solution that addresses the limitations of existing solutions in the Holter market. Bioheart is a personal cardiac monitoring solution for consumers. Biocare is a cardiac disease management platform for chronic care management and remote patient monitoring.